D-0403-2022 Class II Terminated

Recalled by Edge Pharma, LLC — Colchester, VT

FDA drug recall D-0403-2022 was initiated by Edge Pharma, LLC on Dec 6, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 7, 2023). Affected quantity: 627 syringes.

Recall details

Product Type
Drugs
Report Date
Feb 2, 2022
Initiation Date
Dec 6, 2021
Termination Date
Jun 7, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
627 syringes

Product description

Gemcitabine, Sterile Intravesical Solution, Preservative Free, 1g/50mL (20 mg/mL), 50 mL per syringe, Single Dose Syringe for Intravesical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1566-50

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

nationwide

Code information

08-2021-18@1 12/14/2021, 08-2021-27@1 12/09/2021, 09-2021-01@4 12/14/2021, 09-2021-08@2 12/21/2021, 09-2021-14@6 01/05/2021, 09-2021-16@4 12/29/2021, 09-2021-17@4 12/30/2021, 09-2021-22@3 01/04/2022 & 10-2021-27@3 02/08/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0403-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0403-2022. Report a data issue: hello@regdatalab.com.